Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prime MedicinePRME -2.80%25 EV-to-OCF is -3.48 as of Jul. 19, 2026. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Prime Medicine ranks better than 50.85% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Prime Medicine's Enterprise Value is $544.35 Mil.
Prime Medicine's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-156.42 Mil. Therefore, Prime Medicine's EV-to-OCF for today is -3.48.
The historical rank and industry rank for Prime Medicine's EV-to-OCF or its related term are showing as below:
PRME'
s EV-to-OCF Range Over the Past 10 Years
Min: -8.43 Med: -2.81 Max: -0.69
Current: -3.48
During the past 6 years, the highest EV-to-OCF of Prime Medicine was -0.69. The lowest was -8.43. And the median was -2.81.
PRME's EV-to-OCF is ranked better than 50.85% of 1412
companies
in the Biotechnology industry
Industry Median: -3.345
vs PRME: -3.48
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prime Medicine's PE Ratio (TTM) for today is calculated as:
Prime Medicine's share price for today is $3.13.
Prime Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Prime Medicine EV-to-OCF Related Terms
Prime Medicine EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Prime Medicine's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prime Medicine's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Prime Medicine's EV-to-OCF falls into.
Prime Medicine's current Enterprise Value is $544.35 Mil.
Prime Medicine's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-156.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (PRME) has a EV-to-OCF of -3.48 as of Jul. 19, 2026. According to the industry distribution chart, Prime Medicine ranks #694 out of 1412 companies in the Biotechnology industry, placing it in the top 49.2%.
Is Prime Medicine's EV-to-OCF too high?
Prime Medicine's current EV-to-OCF is -3.48. Based on the distribution chart, Prime Medicine ranks #694 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's EV-to-OCF compare to EIKN and CRMD?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #694 out of 1412 companies for EV-to-OCF. This puts Prime Medicine in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Prime Medicine's current EV-to-OCF is -3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current EV-to-OCF of -3.48. The current EV-to-OCF is -3.48. Prime Medicine's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Prime Medicine (PRME), the current EV-to-OCF is -3.48 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
